Design Therapeutics (DSGN) Cash from Financing Activities (2020 - 2026)

Design Therapeutics has reported Cash from Financing Activities for 7 years, with the latest figure at $605000.0 in Q2 2026.

• Cash from Financing Activities for Q2 2026 came in at $605000.0, up 67.59% year-over-year; the trailing twelve-month figure through Jun 2026 was $45.9 million (up 6982.25% YoY), and the FY2025 annual result was $25.7 million, up 4917.15% from the prior year.
• Cash from Financing Activities eased to $605000.0 in Q2 2026, from $19.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $25.3 million in Q4 2025 and troughed at -$202000.0 in Q2 2022.
• A 5-year average of $3.0 million and a median of $153500.0 in 2022 frame the typical range for Cash from Financing Activities.
• The widest annual swing landed in 2022, when Cash from Financing Activities plunged 4140.0%; it then surged 86569.57% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at $130000.0 in 2022, then soared by 285.38% to $501000.0 in 2023, then plunged by 47.5% to $263000.0 in 2024, then soared by 9526.24% to $25.3 million in 2025, then plunged by 97.61% to $605000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $605000.0 in Q2 2026, $19.9 million in Q1 2026, and $25.3 million in Q4 2025.